Interleukin-1β converting enzyme (caspase-1) in intestinal inflammation

Biochemical Pharmacology

Volumn 64, Issue 1, 2002, Pages 1-8

  Siegmund, Britta ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Experimental colitis; IL 18; Il 1 ; Inflammatory bowel disease; Interleukin 1 converting enzyme

Indexed keywords

ANTIINFLAMMATORY AGENT; COMPLEMENTARY RNA; CYTOKINE ANTIBODY; DEXTRAN SULFATE; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; PRALNACASAN; RECOMBINANT INTERLEUKIN 18 ANTAGONIST; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG; ENZYME INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 8;

ARTICLE; CHRONIC INFLAMMATION; COLITIS; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE SEVERITY; ENZYME ACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; HUMAN; INTESTINE INFECTION; INTESTINE MUCOSA; KNOCKOUT MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TH1 CELL; ANIMAL; DRUG ANTAGONISM; ENTERITIS; ENZYMOLOGY; METABOLISM; REVIEW;

ANIMALS; CASPASE 1; ENZYME INHIBITORS; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-1; INTERLEUKIN-18; INTERLEUKIN-8;

EID: 0036628565     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)01064-X     Document Type: Note

References (82)

1. Inflammatory bowel disease: Etiology and pathogenesis
2. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
3. Antibodies to interleukin 12 abrogate established experimental colitis in mice
4. T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon γ expression by T cells
5. Interleukin-18 and interleukin-1β: Two cytokine substrates for ICE (caspase-1)
6. Human ICE/CED-3 protease nomenclature
7. Activation of interferon-γ inducing factor mediated by interleukin-1β converting enzyme
8. Structure and mechanism of interleukin-1β converting enzyme
9. Ligation of CD40 activates interleukin 1β-converting enzyme (caspase-1) activity in vascular smooth muscle and endothelial cells and promotes elaboration of active interleukin 1β
10. Expression of interleukin 1β and interleukin 1β converting enzyme by intestinal macrophages in health and inflammatory bowel disease
11. The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells
12. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1β-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases
13. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation
14. Nitric oxide prevents IL-1β and IFN-γ-inducing factor (IL-18) release from macrophages by inhibiting caspase-1 (IL-1β-converting enzyme)
15. Interleukin-18 regulation of interferon γ production and cell proliferation as shown in interleukin-1β-converting enzyme (caspase-1)-deficient mice
16. Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal Escherichia coli and Salmonella typhimurium endotoxemia
17. Severity and mortality of experimental pancreatitis are dependent on interleukin-1 converting enzyme (ICE)
18. Differential effects of caspase-1/interleukin-1β-converting enzyme on acinar cell necrosis and apoptosis in severe acute experimental pancreatitis
19. Therapeutic application of caspase 1/interleukin-1β-converting enzyme inhibitor decreases the death rate in severe acute experimental pancreatitis
20. Selective interleukin-1 converting enzyme (ICE/Caspase-1) inhibition with pralnacasan (HMR3480/VX-740) reduces inflammation and joint destruction in murine type II collagen-induced arthritis (CIA)
21. IL-18 regulates IL-1β-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1
22. Morphology of rectal mucosa of patients with shigellosis
23. In situ characterization of inflammatory responses in the rectal mucosae of patients with shigellosis
24. Shigella flexneri induces apoptosis in infected macrophages
25. Role of interleukin-1 in the pathogenesis of experimental shigellosis
26. Interleukin 1 is released by murine macrophages during apoptosis induced by Shigella flexneri
27. In vivo apoptosis in Shigella flexneri infections
28. The interleukin 1β-converting enzyme, caspase 1, is activated during Shigella flexneri-induced apoptosis in human monocyte-derived macrophages
29. Problems in recognition and diagnosis of amebiasis: Estimation of the global magnitude of morbidity and mortality
30. Relapsing amoebic colitis of 12 year's standing exacerbated by corticosteroids
31. Protozoa. Amebiasis
32. Amebic colitis mistaken for inflammatory bowel disease
33. Entamoeba histolytica cysteine proteinases with interleukin-1 beta converting enzyme (ICE) activity cause intestinal inflammation and tissue damage in amoebiasis
34. Molecular basis of the interaction of Salmonella with the intestinal mucosa
35. Salmonella pathogenicity island 2-dependent macrophage death is mediated in part by the host cysteine protease caspase-1
36. Salmonella exploits caspase-1 to colonize Peyer's patches in a murine typhoid model
37. Salmonella-induced macrophage death: The role of caspase-1 in death and inflammation
38. IL-1β-converting enzyme (caspase-1) in intestinal inflammation
39. ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs
40. In vivo efficacy of the Il-1β converting enzyme inhibitor pralnacasan in DSS-induced murine colitis
41. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family
42. Cloning of a new cytokine that induces IFN-γ production by T cells
43. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones
44. Coagulation of whole blood stimulates interleukin-1β gene expression
45. Hyperosmotic stress as a stimulant for proinflammatory cytokine production
46. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1β are differentially regulated in human blood mononuclear cells and mouse spleen cells
47. Involvement of caspase-1 and caspase-3 in the production and processing of mature human interleukin 18 in monocytic THP.1 cells
48. Regulation of IL-18 (IFN-γ-inducing factor) gene expression
49. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling
50. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP
51. Purification and characterization of the human interleukin-18 receptor
52. Cloning of the cDNA for human IFN-γ-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein
53. Transcriptional regulation of the human prointerleukin 1β gene
54. Human pro-IL-1β gene expression in monocytic cells is regulated by two distinct pathways
55. A novel secretory pathway for interleukin-1β, a protein lacking a signal sequence
56. Interleukin 1: The patterns of translation and intracellular distribution support alternative secretory mechanisms
57. Biologic basis for interleukin-1 in disease
58. Processing and activation of pro-interleukin-16 by caspase-3
59. Generation of biologically active interleukin-1β by proteolytic cleavage of the inactive precursor
60. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presence of activated neutrophils or purified proteinase 3
61. Multiple biological activities of human recombinant interleukin 1
62. Human keratinocytes produce but do not process pro-interleukin-1 (IL-1) beta. Different strategies of IL-1 production and processing in monocytes and keratinocytes
63. Rapid and specific conversion of precursor interleukin 1β (IL-1β) to an active IL-1 species by human mast cell chymase
64. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice
65. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene
66. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis
67. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease
68. + T lymphocytes
69. IFN-γ-dependent and -independent mechanisms in adverse effects caused by concomitant administration of IL-18 and IL-12
70. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-γ dependent manner
71. Bioactive IL-18 expression is up-regulated in Crohn's disease
72. IL-18, a novel immunoregulatory cytokine, is up-regulated in Crohn's disease: Expression and localization in intestinal mucosal cells
73. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-γ and TNF-α production
74. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines
75. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice
76. Activation of natural killer T cells by α-galactosylceramide in the presence of CD1d provides protection against colitis in mice
77. Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohn's disease
78. Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-α production in mice
79. Interleukin-18 binding protein: A novel modulator of the Th1 cytokine response
80. Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18
81. Treatment of T cell-dependent experimental colitis in SCID mice by local administration of an adenovirus expressing IL-18 antisense mRNA
82. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo